toxicity
Nivolumab Substituted for Brentuximab Vedotin in Hodgkin Therapy Improves Outcomes
In older patients with advanced-stage classic Hodgkin lymphoma (cHL), outcomes are particularly improved with lower ...
FEBRUARY 21, 2024
Are We Appropriately Monitoring Antineoplastic Drug Toxicity in the ‘Real World’?
The most striking difference between antineoplastic and other pharmaceutical agents is the toxicity profile that is ...
MARCH 8, 2017
Proton RT of Recurrent NSCLC Feasible in Selected Patients
Reirradiation with proton radiation therapy is possible in patients with locoregionally recurrent non-small cell ...
NOVEMBER 23, 2016
The NCCN Launches Campaign To Prevent Deadly Medical Error
The National Comprehensive Cancer Network is beckoning the medical community to take notice of how important it is ...
NOVEMBER 10, 2016
Immunotherapy Ushers in New Era of Toxicity Management
Immunotherapy is becoming an integral player in cancer treatment, and with so many products in clinical trials, ...
OCTOBER 6, 2016
Extended Adjuvant AIs: Safe and Active, but Not Much Good
Paul E. Goss, MD, PhD, presented the 6.3-year analysis of the MA.17R breast cancer trial at the 2016 annual meeting ...
SEPTEMBER 19, 2016
